Bactericidal activity of an imidazo[1, 2- A]pyridine using a mouse M. tuberculosis infection model

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Cheng, Yong ^a   Moraski, Garrett C ^a   Cramer, Jeffrey ^b   Miller, Marvin J ^a   Schorey, Jeffrey S ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERICIDE; IMIDAZO[1,2 A]PYRIDINE; ISONIAZID; N [4 (4 CHLOROPHENOXY)BENZYL] 2,7 DIMETHYLIMIDAZO[1,2 A]PYRIDINE 3 CARBOXAMIDE; ND 09759; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; LUNG; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; SINGLE DRUG DOSE; SPLEEN; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; FEMALE; HEP G2 CELLS; HUMANS; IMIDAZOLES; INFLAMMATION; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; PYRIDINES; TUBERCULOSIS;

EID: 84900296845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087483     Document Type: Article

References (33)

1. World Health Organization (2010) Global tuberculosis control 2010.
2. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, et al. (2010) Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 375: 1830-1843.
3. Prasad R, Verma SK, Sahai S, Kumar S, Jain A (2006) Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients. Indian J Chest Dis Allied Sci 48: 183-186.
4. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X (2010) Global tuberculosis drug development pipeline: the need and the reality. Lancet 375: 2100-2109.
5. Lönnroth K, Castro KG, Chakaya JM, Chauhan LS, Floyd K, et al. (2010) Tuberculosis control and elimination 2010-50: cure, care, and social development. Lancet 375: 1814-1829.
6. Moraski GC, Markley LD, Hipskind PA, Boshoff H, Cho S, et al. (2011) Advent of Imidazo[1,2-a]pyridine-3-carboxamides with Potent Multi- and Extended Drug Resistant Antituberculosis Activity. ACS Med Chem Lett 2: 466-470.
7. Moraski GC, Markley LD, Cramer J, Hipskind PA, Boshoff H, et al. (2013) Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and nM Activity vs. Mycobacterium tuberculosis. ACS Med Chem Lett 4(7): 675-679.
8. Ollinger J, Bailey MA, Moraski GC, Casey A, Florio S, et al. (2013) A dual readout assay to evaluate the potency of compounds active against Mycobacterium tuberculosis. PLoS One 8: e60531.
9. Abrahams KA, Cox JA, Spivey VL, Loman NJ, Pallen MJ, et al. (2012) Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB. PLoS One 7: e52951.
10. Pethe K, Bifani P, Jang J, Kang S, Park S, et al. (2013) Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19: 1157-1160.
11. Sweeney KA, Dao DN, Goldberg MF, Hsu T, Venkataswamy MM, et al. (2011) A recombinant Mycobacterium smegmatis induces potent bactericidal immunity against Mycobacterium tuberculosis. Nat Med 17: 1261-1268.
12. North RJ, Jung YJ (2004) Immunity to tuberculosis. Annu Rev Immunol 22: 599-623. (Pubitemid 38680435)
13. Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, et al. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 3: e466.
14. Protopopova M, Hanrahan C, Nikonenko B, Samala R, Chen P, et al. (2005) Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. J Antimicrob Chemother 56: 968-974. (Pubitemid 41631930)
15. Stover CK, Warrener P, VanDevanter DR, Sherman DR, Arain TM, et al. (2000) A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405: 962-966. (Pubitemid 30435054)
16. Alcala L, Ruiz-Serrano MJ, Perez-Fernandez Turegano C, Garcia De Viedma D, Diaz-Infantes M, et al. (2003) In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs. Antimicrob Agents Chemother 47: 416-417. (Pubitemid 36070399)
17. Engohang-Ndong J (2012) Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment. Expert Opin Investig Drugs 21: 1789-1800.
18. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, et al. (2003) Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47: 2118-2124. (Pubitemid 36753560)
19. Jayaram R, Shandil RK, Gaonkar S, Kaur P, Suresh BL, et al. (2004) Isoniazid pharmacokinetics-pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 48: 2951-2957. (Pubitemid 38989160)
20. Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, et al. (2009) Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 53: 4178-4184.
21. Grosset J, Almeida D, Converse PJ, Tyagi S, Li SY, et al. (2012) Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide. Proc Natl Acad Sci U S A 109: 15001-15005.
22. Grosset J, Truffot-Pernot C, Lacroix C, Ji B (1992) Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice. Antimicrob Agents Chemother 36: 548-551.
23. Nuermberger EL, Spigelman MK, Yew WW (2010) Current development and future prospects in chemotherapy of tuberculosis. Respirology 15: 764-778.
24. Lienhardt C, Raviglione M, Spigelman M, Hafner R, Jaramillo E, et al. (2012) New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 205 Suppl 2: S241-249.
25. Ginsberg A (2011) The TB Alliance: overcoming challenges to chart the future course of TB drug development. Future Med Chem 3: 1247-1252.
26. Gomez JE, McKinney JD (2004) M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb) 84: 29-44. (Pubitemid 38082931)
27. Warner DF, Mizrahi V (2006) Tuberculosis chemotherapy: the influence of bacillary stress and damage response pathways on drug efficacy. Clin Microbiol Rev 19: 558-570. (Pubitemid 44134310)
28. Connolly LE, Edelstein PH, Ramakrishnan L (2007) Why is long-term therapy required to cure tuberculosis? PLoS Med 4: e120.
29. Dhar N, McKinney JD (2007) Microbial phenotypic heterogeneity and antibiotic tolerance. Curr Opin Microbiol 10: 30-38. (Pubitemid 46216877)
30. Barry CE 3rd, Boshoff HI, Dartois V, Dick T, Ehrt S, et al. (2009) The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7: 845-855.
31. Young D (2009) Animal models of tuberculosis. Eur J Immunol 39: 2011-2014.
32. Kaushal D, Mehra S, Didier PJ, Lackner AA (2012) The non-human primate model of tuberculosis. J Med Primatol 41: 191-201.
33. Goldberg DE, Siliciano RF, Jacobs WR Jr (2012) Outwitting evolution: fighting drug-resistant TB, malaria, and HIV. Cell 148: 1271-1283.